Home
ACTL Immunotherapy
Functional Mechanism
Advantages
Safety
Indications
Protocols
Steps
Patents
Translational Medicine
Treatment & Prevent
Conditions
Case Studies
Cooperative Hospital
Early Detection
Prevention
Nursing & Care
News
Partnership
About Us
Company Introduction
Our Culture
Milestones
Qualification & Honor
Team of Experts
Activities
Jobs
Contact Us
简体
繁体
英文
Coperate News
Coperate News
Industrial News
Policies & Regulations
05-11 2021
Study on the resistance of ACTL to patients with non-small cell lung adenocarcinoma
The most common targeted therapy for non-small cell lung adenocarcinoma (NSCLC) is epidermal c...
Details
03-02 2021
Immunotherapy can intervene and prevent metastasis
Human emotions often affect the progression of the disease, especially ...
Details
02-03 2021
Shenzhen Yishi Kangning Biotechnology Co., Ltd. won another invention patent
On September 28, 2020, the State Intellectual Property Office granted Shenzhen Yishi Kangni...
Details
02-03 2021
The characteristics of adeno-associated virus (AAV) and its application in ACTL technology
Adeno-associated virus (adeno-associated virus, AAV) belongs to the Parvoviridae family. Membe...
Details
02-03 2021
Good news: ACTL treatment of prostate cancer clinical research project approved by the National Health Commission
As the living standards of our people are improving, the incidence of prostate cancer is also on th...
Details
<<
1
2
3
4
5
>>
10
